EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram

Ayse Irem Yasin, Mahmut Uluganyan, Zehra Sucuoglu Isleyen, Atakan Topcu, Abdallah Tm Shbair, Melih Simsek, Mehmet Besiroglu, Yeliz Emine Ersoy, Hacı Mehmet Türk, Mesut Seker

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08702-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Ayse Irem Yasin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Bezmialem Vakıf University, Huzur Mah. Cumhuriyet Cad., 34396, Istanbul, Turkey. ayseiremyasin@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Electrocardiography, Ambulatory, Purines, Aminopyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bezmialem Vakif University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to evaluate cardiac safety profile of ribociclib with 24-h rhythm Holter ECG. Material and method Forty-two female metastatic breast cancer patients were included in the study. Rhythm Holter ECG was performed before starting treatment with ribociclib and after 3 months of the treatment initiation.

Results

The mean age of the patients was 56.36 ± 12.73. 52.4% ( n = 22) of the patients were using ribociclib in combination with fulvestrant and 47.6% ( n = 20) with aromatase inhibitors. None of the patients developed cardiotoxicity. When the rhythm Holter results before and in third month of the treatment were compared, there was no statistically significant difference.

Conclusion

This is the first study evaluating effects of ribociclib treatment on cardiac rhythm with Holter ECG. The findings suggested ribociclib has a low risk of causing early cardiotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsElectrocardiography, AmbulatoryPurinesAminopyridinesHumansFemaleMiddle AgedAgedAdultCardiotoxicityAntineoplastic AgentsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

CardiotoxicityHolter ECGHormon-positive breast cancerRibociclib

Substanzen

ribociclibPurinesAminopyridinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Bezmialem Vakıf University, Huzur Mah. Cumhuriyet Cad., 34396, Istanbul, Turkey. ayseiremyasin@gmail.com.
  • Department of Cardiology, Bezmialem Vakıf University, Huzur Mah. Cumhuriyet Cad., 34396, Istanbul, Turkey.
  • Department of Medical Oncology, Bezmialem Vakıf University, Huzur Mah. Cumhuriyet Cad., 34396, Istanbul, Turkey.
  • Department of General Surgery, Bezmialem Vakıf University, Huzur Mah. Cumhuriyet Cad. , 34396, Istanbul, Turkey.

Förderung

  • Bezmialem Vakif University

Zitieren

APA

Yasin, A. I., Uluganyan, M., Isleyen, Z. S., Topcu, A., Shbair, A. T., Simsek, M., Besiroglu, M., Ersoy, Y. E., Türk, H. M., & Seker, M. (2024). Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08702-0

Vancouver

Yasin AI, Uluganyan M, Isleyen ZS, Topcu A, Shbair AT, Simsek M, et al. Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08702-0

BibTeX
@article{Yasin2024,
  author = {Yasin, Ayse Irem and Uluganyan, Mahmut and Isleyen, Zehra Sucuoglu and Topcu, Atakan and Shbair, Abdallah Tm and Simsek, Melih and Besiroglu, Mehmet and Ersoy, Yeliz Emine and Türk, Hacı Mehmet and Seker, Mesut},
  title = {Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08702-0}
}
Kostenlos starten →